Objective This study aimed to quantify the health and productivity burden of migraines in Australia, measured by quality‐adjusted life years (QALYs), productivity‐adjusted life years (PALYs, a novel measure of productivity), and associated health‐care and broader economic costs. Methods A Markov state‐transition model was constructed to simulate follow‐up of Australians aged 20‐64 years over the next 10 years. The model was first run using current prevalence estimates of migraine. It was then rerun assuming that people with migraine hypothetically did not have the condition. Differences in outcomes between the 2 model simulations represented the health and productivity burden attributable to migraine. All data inputs were obtained from published sources. Gross domestic product (GDP) per equivalent full‐time worker in Australia was used to reflect the cost of each PALY (AU$177,092). Future costs and outcomes were discounted by 5% annually. Results Currently, 1,274,319 million (8.5%) Australians aged 20‐64 years have migraine. Over the next 10 years, migraine was predicted to lead to a loss of 2,577,783 (95% confidence interval [CI] 2,054,980 to 3,000,784) QALYs among this cohort (2.02 per person and 2.43% of total QALYs), and AU$1.67 (95% CI $1.16 to $2.37) billion in health‐care costs (AU$1313 per person, 95% CI $914 to $1862). There would also be 384,740 (95% CI 299,102 to 479,803) PALYs lost (0.30 per person and 0.53% of total PALYs), resulting in AU$68.13 (95% CI $44.42 to $98.25) billion of lost GDP (AU$53,467 per person, 95% CI $34,855 to $77,102). Conclusion Migraines impose a substantial health and economic burden on Australians of working age. Funding interventions that reduce the prevalence of migraines and/or its effects are likely to provide sound return on investment.

years. However, data on the economic burden of SMA1 since FDA approval of the first effective disease-modifying therapy (nusinersen, 12/23/2016) are limited. We previously conducted a retrospective evaluation of healthcare resource utilization (HCRU) and costs in patients with SMA1, overall and following nusinersen initiation; however, this study was limited by short follow-up duration (median, 7.9 months). Here, we expand these findings with additional/updated observations and greater follow-up. Methods: Patients with SMA1 were identified in Symphony Health's Integrated Dataverse ® (09/01/2016-08/31/2019). HCRU was assessed from the index date (first SMA diagnosis date after 12/23/2016) until the last date of clinical activity or end of available data. For nusinersen-treated patients, HCRU was also assessed following treatment initiation. Results: We identified 449 patients with SMA1 (55.2% female; median follow-up, 12.4 months). Patients with SMA1 overall and nusinersen-treated patients (n=59) averaged, respectively, 50.6 vs. 46.8 days with medical visits/year (inpatient, 8.2 vs. 4.7; respiratory failure-related, 9.5 vs. 7.4). All of these values, with the exception of average inpatient days/year among nusinersentreated patients, are lower compared with our earlier analysis. HCRU is expected to translate into substantial healthcare costs, both overall and in nusinersen-treated patients. Updated cost data available at the time of the conference will be presented. An important limitation is that, while .59 patients may have received nusinersen, HCRU could only accurately be assessed among patients with recorded nusinersenassociated procedures or drug codes. Conclusions: When evaluated over a longer follow-up period, HCRU was generally lower than previously estimated, suggesting that the burden of SMA1 may be higher around date of diagnosis. Nonetheless, results indicate that the burden associated with SMA1 remains substantial, including among patients receiving ongoing disease-modifying therapy. Funding: AveXis, Inc., a Novartis company.